14 completed, 2 unknown. 6 Phase 4, 2 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 5, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Albuterol, Ipratropium Drug Combination: new trials by email Literature Review of Albuterol, Ipratropium Drug Combination trials Research Report on Albuterol, Ipratropium Drug Combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators Fentanyl Citrate, Combivent - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Dr. Denis O'Donnell | 20 | 2017-09-20 | 2024-04-03 |
| Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus Ipratropium, 0.9% Sodium Chloride, Albuterol - Status Asthmaticus | Phase 1 | Completed | University Hospitals Cleveland Medical Center | 30 | 2016-09-05 | 2019-04-18 |
| Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD indacaterol/glycopyrronium 110/50 Breezhaler®, Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation - COPD | Phase 4 | Completed | Wouter H. van Geffen | 40 | 2015-12-01 | 2017-10-11 |
| Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease Combination ipratropium/salbutamol or placebo (nebulization) - Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease | Not applicable | Unknown | Laval University | 40 | 2012-09-01 | 2013-09-18 |
| Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) Budesonide, budesonide/formoterol, Ipratropium/albuterol - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | National Jewish Health | 46 | 2012-04-01 | 2021-01-19 |
| Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC), Anticholinergics (AC) - Pulmonary Disease, Chronic Obstructive | Completed | GlaxoSmithKline | 2849 | 2011-03-01 | 2017-05-16 | |
| Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 470 | 2009-11-01 | 2014-10-23 |
| Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies fluticasone propionate/salmeterol xinafoate combination, Other maintenance Treatments (OMT) - Pulmonary Disease, Chronic Obstructive | Completed | GlaxoSmithKline | 5677 | 2009-11-01 | 2017-06-27 | |
| Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD) fluticasone/salmeterol combination (FSC) 250/50mcg, tiotropium, ipratropium bromide alone or in fixed dose combination with albuterol - Pulmonary Disease, Chronic Obstructive | Completed | GlaxoSmithKline | 76130 | 2009-07-01 | 2017-07-02 | |
| The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Salmeterol/Fluticasone Propionate - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Unknown | Fudan University | 450 | 2009-07-01 | 2010-11-19 |
| GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD) Combination ipratropium/salbutamol or placebo (nebulization) - Mild Chronic Obstructive Pulmonary Disease, Respiratory Symptoms | Completed | Laval University | 53 | 2009-02-01 | 2011-05-26 | |
| 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent - Asthma | Phase 2 | Completed | Boehringer Ingelheim | 226 | 2008-12-01 | 2014-02-14 |
| Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg) - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 1480 | 2006-11-01 | 2014-06-13 |
| A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients. tiotropium, Combivent (Ipratropium/Albuterol) - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 349 | 2006-07-01 | 2014-05-16 |
| Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients Combivent - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Queen's University | 12 | 2006-03-01 | 2011-04-19 |
| A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Placebo Combivent HFA, Combivent HFA, Combivent (CFC) - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Boehringer Ingelheim | 66 | 2000-10-01 | 2018-08-31 |
Pulmonary Disease, Chronic Obstructive (14) · Dyspnea (2) · Motor Activity (2) · Asthma (1) · Signs and Symptoms, Respiratory (1) · Status Asthmaticus (1)
Boehringer Ingelheim (5) · GlaxoSmithKline (3) · Laval University (2) · Dr. Denis O'Donnell (1) · Fudan University (1) · National Jewish Health (1) · Queen's University (1) · University Hospitals Cleveland Medical Center (1) · Wouter H. van Geffen (1)
United States (6) · Canada (4) · Argentina (1) · China (1) · France (1) · Greece (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Russia (1) · South Africa (1) · South Korea (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1)
Barry J Make, MD (1) · Denis E O'Donnell, MD (1) · Denis E O'Donnell, MD, FRCPC (1) · Edwin K Silverman, MD, PhD (1) · Huib AM Kerstjens, prof. dr. (1) · James D Crapo, MD (1) · Wouter H van Geffen, MD (1)
PMID 19711095, PMID 20172704, PMID 23658479, PMID 25906326, PMID 27130202